IRIS
CASADEI GARDINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 797
NA - Nord America 755
AS - Asia 465
SA - Sud America 11
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 1
Totale 2.035
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 749
SE - Svezia 464
SG - Singapore 259
CN - Cina 180
RU - Federazione Russa 170
IT - Italia 80
FI - Finlandia 25
DE - Germania 21
NL - Olanda 15
GB - Regno Unito 8
IE - Irlanda 7
IN - India 7
BR - Brasile 6
IR - Iran 6
JP - Giappone 6
AR - Argentina 4
CA - Canada 4
EU - Europa 4
FR - Francia 3
PH - Filippine 3
A1 - Anonimo 2
AT - Austria 2
MX - Messico 2
AU - Australia 1
BD - Bangladesh 1
CO - Colombia 1
CZ - Repubblica Ceca 1
ES - Italia 1
HK - Hong Kong 1
IL - Israele 1
TR - Turchia 1
Totale 2.035
Salva come PNG Salva come JPEG
Città #
New York 202
Lawrence 149
Princeton 149
Singapore 129
Shanghai 59
Moscow 51
Ashburn 46
Boardman 45
Helsinki 22
Milan 15
Dallas 11
Guangzhou 10
Rome 9
Hanover 8
Seattle 8
Shenzhen 8
Washington 8
Beijing 7
Dublin 7
Wuxi 7
Dronten 4
London 4
Los Angeles 4
Martinez 4
Santa Clara 4
Amsterdam 3
Durham 3
Lappeenranta 3
Taizhou 3
Xi'an 3
Berlin 2
Brighton 2
Foggia 2
Fukushima 2
Jiaxing 2
Kish 2
Lucca 2
Ludhiana 2
Lyon 2
Manila 2
Mexico City 2
Naples 2
Pune 2
Rimini 2
Roseto degli Abruzzi 2
Sant'Antimo 2
Tokyo 2
Visakhapatnam 2
Weitang 2
Zhuji 2
Aioicho 1
Andover 1
Ankara 1
Ann Arbor 1
Bari 1
Birmingham 1
Bologna 1
Borås 1
Boston 1
Brescia 1
Brisbane 1
Central 1
Chicago 1
Chongqing 1
Clifton 1
Delhi 1
Dongguan 1
Foshan 1
Giugliano in Campania 1
Goala Bazar 1
Hamm 1
Jinhua 1
João Pessoa 1
Kashan 1
Leawood 1
Lu'an 1
Macael 1
Mountain View 1
Naaldwijk 1
Nanjing 1
New Orleans 1
Noicattaro 1
Nuremberg 1
Oakland 1
Oldham 1
Pisa 1
Pontirolo Nuovo 1
Quanzhou 1
Redwood City 1
Rockville 1
Sacramento 1
San Francisco 1
Sanming 1
Tarlac City 1
Venezia 1
Verdellino 1
Vezzano sul Crostolo 1
Vienna 1
Weifang 1
Winnipeg 1
Totale 1.075
Salva come PNG Salva come JPEG
Nome #
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 32
Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities 25
EUS-guided GastroEnterostomy for management of malignant Gastric Outlet Obstruction: a prospective cohort study with matched comparison with Enteral Stenting 24
Platelets and hepatocellular cancer: Bridging the bench to the clinics 23
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 21
ROS1 rearrangements are uncommon in biliary tract cancers 21
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 20
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 20
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 20
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 20
BRAF-mutated colorectal cancer: Clinical and molecular insights 20
Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study 20
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 19
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 19
Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report and results from a cytoflourimetric assay of platelet fibrinogen receptor 19
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 19
Mtor pathway expression as potential predictive biomarker in patients with advanced neuroendocrine tumors treated with everolimus 19
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 19
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 19
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 18
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 18
Alpha-fetoprotein surge following high-dose chemotherapy in germ cell tumours 18
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 18
BRCA in gastrointestinal cancers: Current treatments and future perspectives 18
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 18
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 18
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease 17
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows 17
1H-NMR based serum metabolomics highlights different specific biomarkers between early and advanced hepatocellular carcinoma stages 17
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 17
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 17
Atezolizumab and bevacizumab in advanced HCC: ready for prime time? 17
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 17
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 16
Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice? 16
Sorafenib for the treatment of unresectable hepatocellular carcinoma: Preliminary toxicity and activity data in dogs 16
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 16
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study (Targeted Oncology, (2020), 15, 1, (115-126), 10.1007/s11523-020-00698-x) 16
Cholangiocarcinoma: new perspectives for new horizons 16
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 16
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 16
Retrospective Evaluation and Significance of Neutrophil-to-Lymphocyte Ratio Prior to and 1 month Following Microwave Ablation of Hepatocellular Carcinoma 15
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 15
Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score-Matched Analysis 15
Immunotherapy for colorectal cancer: where are we heading? 15
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 15
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 15
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 14
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis? 14
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 14
Hemangioblastoma of the gastrointestinal tract: A first case 14
Radiofrequency Ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival 14
Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: a case report 14
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 14
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 14
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 14
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: Results from a retrospective analysis of the HCC-AVR group 14
NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus 14
Sarcopenia in gastric cancer: when the loss costs too much 14
EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model? 14
Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study 14
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials 14
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 14
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 14
Developments in predictive biomarkers for hepatocellular carcinoma therapy 14
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 14
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 14
Predictive and prognostic factors in HCC patients treated with sorafenib 14
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 14
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life 14
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 14
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 13
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 13
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: Indicators of suspected adverse reactions 13
Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation 13
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy 13
Oxidative Molecular Mechanisms Underlying Liver Diseases: From Systems Biology to the Personalized Medicine 13
Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals 13
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial 13
NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment 13
Improved stool DNA integrity method for early colorectal cancer diagnosis 13
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 13
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 13
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib 13
The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT 13
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 13
The Italian Rare Pancreatic Exocrine Cancer Initiative 13
Monofocal hepatocellular carcinoma: How much does size matter? 13
KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC) 13
Metabolic disorders across hepatocellular carcinoma in Italy 13
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis 13
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 12
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 12
Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: Case report 12
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab 12
Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study 12
Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort 12
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 12
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 12
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study 12
Totale 1.566
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.417
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.417
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021130 0 0 0 77 0 51 1 1 0 0 0 0
2021/2022100 0 0 0 40 2 5 15 22 6 2 0 8
2022/2023842 325 171 70 12 2 123 25 46 49 5 6 8
2023/2024661 35 18 58 54 33 226 73 44 0 11 24 85
2024/2025554 349 70 73 32 30 0 0 0 0 0 0 0
Totale 2.287